Data from the Checkmate 025 trial showed that higher levels of PD-L1 expression are associated with poorer survival in RCC, but did not support PD-L1 as a marker predictive of treatment benefit in RCC; a benefit was observed, however, with nivolumab irrespective of PD-L1 expression (62). Here, CD274 is linked to renal cell adenocarcinoma.